United we stand : double targeting of CD79B and CD20 in diffuse large B-cell lymphoma
- Tarantelli, Chiara ORCID Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
- Bertoni, Francesco ORCID Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
- 2022
Published in:
- British Journal of Haematology. - 2022, vol. 199, p. 169–170
English
Polatuzumab vedotin is antibody-drug conjugate (ADC) targeting CD79B approved for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma when given in combination with bendamustine and rituximab. The report by Kawasaki et al. provide hints on what might be happening in lymphoma cells exposed to polatuzumab vedotin and to rituximab and on potential mechanism of resistance to the ADC.
- Collections
- Language
-
- English
- Classification
- Medicine
- License
-
CC BY-NC-ND
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1111/bjh.18384
- ARK ark:/12658/srd1322803
- Persistent URL
- https://localhost:5000/ark:/12658/srd1322803
Export to…
Statistics
Document views: 155
File downloads:
- Bertoni_2022_Wiley_bjhaem: 344